title: Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients.
abstract: OBJECTIVE
  The current validated assay to determine tropism of HIV variants is Trofile, which has some limitations. The aim of this work was to correlate the virological response to a short-term maraviroc exposure with Trofile.
  
  
  METHODS
  From 1 July 2008 to 1 March 2009, 34 consecutive HIV-infected patients with detectable viral load during the last 6 months began an 8 day exposure to maraviroc (MCT group); six HIV-infected patients without antiretroviral therapy received no treatment (control group). Plasma viral load was evaluated on days 0, 2, 5 and 8. Baseline Trofile was performed in MCT group patients. The maraviroc clinical test (MCT) was considered positive if viral load was undetectable (< 40 HIV-RNA copies/mL) or a reduction > or = 1 log(10) HIV-RNA copies/mL was achieved after 8 days of maraviroc exposure.
  
  
  RESULTS
  Global concordance between MCT and Trofile was 93.5%. In patients with R5 virus according to Trofile, MCT was positive in 19/20 (concordance 95%); in patients with dual/mixed virus, MCT was negative in 10/11 (concordance 90.9%). An additional phenotypic tropism assay was performed in patients with discordance between MCT and Trofile, being concordant with MCT in both cases. Three patients showed a non-reportable Trofile result, and all of them achieved undetectability after MCT.
  
  
  CONCLUSIONS
  A clinical approach like short-term maraviroc exposure could be an additional resource to genetic and phenotypic HIV tropism assays. This clinical approach shows high concordance with Trofile, and could allow patients with non-reportable results by Trofile to benefit from maraviroc therapy.
authors: Laboratory of Immunovirology, Biomedicine Institute of Seville, Service of Infectious Diseases, Virgen del Rocío University Hospital, Seville, Spain.
authors: Miguel
authors: M
authors: Genebat
authors: Ezequiel
authors: E
authors: Ruiz-Mateos
authors: Juan A
authors: JA
authors: León
authors: Alejandro
authors: A
authors: González-Serna
authors: Ildefonso
authors: I
authors: Pulido
authors: Inmaculada
authors: I
authors: Rivas
authors: Sara
authors: S
authors: Ferrando-Martínez
authors: Berta
authors: B
authors: Sánchez
authors: Ma Angeles
authors: MA
authors: Muñoz-Fernández
authors: Manuel
authors: M
authors: Leal
mesh_terms: D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002648:Child; D003510:Cyclohexanes / Q000494:pharmacology*; D005260:Female; D006678:HIV / Q000187:drug effects* / Q000502:physiology*; D015658:HIV Infections / Q000821:virology*; D006801:Humans; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D015728:Receptors, HIV / Q000032:analysis*; D014230:Triazoles / Q000494:pharmacology*; D019562:Viral Load; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents; D003510:Cyclohexanes; D015728:Receptors, HIV; D014230:Triazoles; D000077592:Maraviroc